MXPA04004491A - Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide. - Google Patents

Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide.

Info

Publication number
MXPA04004491A
MXPA04004491A MXPA04004491A MXPA04004491A MXPA04004491A MX PA04004491 A MXPA04004491 A MX PA04004491A MX PA04004491 A MXPA04004491 A MX PA04004491A MX PA04004491 A MXPA04004491 A MX PA04004491A MX PA04004491 A MXPA04004491 A MX PA04004491A
Authority
MX
Mexico
Prior art keywords
lir
agonist
agent
patient
cells
Prior art date
Application number
MXPA04004491A
Other languages
English (en)
Spanish (es)
Inventor
Tedla Nicodemus
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA04004491A publication Critical patent/MXPA04004491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
MXPA04004491A 2001-11-14 2002-11-12 Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide. MXPA04004491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33589901P 2001-11-14 2001-11-14
PCT/US2002/036372 WO2003041650A2 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MXPA04004491A true MXPA04004491A (es) 2005-05-16

Family

ID=30770813

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004491A MXPA04004491A (es) 2001-11-14 2002-11-12 Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide.

Country Status (8)

Country Link
US (1) US20050238643A1 (OSRAM)
EP (1) EP1453540A4 (OSRAM)
JP (1) JP2005532256A (OSRAM)
AU (1) AU2002360376B2 (OSRAM)
CA (1) CA2466118A1 (OSRAM)
MX (1) MXPA04004491A (OSRAM)
PL (1) PL374463A1 (OSRAM)
WO (1) WO2003041650A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
PE20091969A1 (es) * 2008-05-13 2010-01-15 Genentech Inc ANTICUERPOS ANTI-PirB
WO2010101192A1 (ja) * 2009-03-03 2010-09-10 国立大学法人九州大学 関節リウマチまたはその関連疾患の予防または治療剤
WO2011091177A1 (en) * 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) * 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2888647A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CA3087166A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
EP4103613A1 (en) * 2020-02-12 2022-12-21 BioInvent International AB Lilrb3 antibody molecules and uses thereof
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031806A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc RECEPTORS AND POLYPEPTIDES
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
CA2398251A1 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Also Published As

Publication number Publication date
WO2003041650A3 (en) 2004-01-29
PL374463A1 (en) 2005-10-17
CA2466118A1 (en) 2003-05-22
AU2002360376B2 (en) 2006-05-18
WO2003041650A2 (en) 2003-05-22
JP2005532256A (ja) 2005-10-27
EP1453540A4 (en) 2005-06-01
EP1453540A2 (en) 2004-09-08
US20050238643A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
US10494416B2 (en) Methods of modulating immune responses using BCMA polypeptide
AU738981B2 (en) Methods and compositions for immunomodulation
US6376459B1 (en) Inhibiting B cell activation with soluble CD40 or fusion proteins thereof
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5620889A (en) Human anti-Fas IgG1 monoclonal antibodies
EP2040730B1 (en) Modulation of nkg2d in hbv patients
EP2295079A2 (en) Method for treating inflammation
US6528055B2 (en) Methods of administering antibodies that specifically bind ACT-4-L-h-1 ligand
PT726952E (pt) Receptor na superfície de células t activadas: act-4
CA2511823A1 (en) Combination therapy with co-stimulatory factors
US20050238643A1 (en) Modulation of lir function to treat rheumatoid arthritis
AU2016227322A1 (en) Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases
US6015559A (en) Fas antagonists
AU2002360376A1 (en) Modulation of LIR function to treat rheumatoid arthritis
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
EP2193790A1 (en) IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
KR100622960B1 (ko) 림프독소（ｌｔ）경로 저해제를 사용한 여포 림프종의 치료 방법
HK1157388A (en) Baff receptor (bcma), an immunoregulatory agent